Jean Jacques Noubiap1, Thomas A Agbaedeng1, Aude Laetitia Ndoadoumgue2, Ulrich Flore Nyaga3, Andre Pascal Kengne4. 1. Centre for Heart Rhythm Disorders, The University of Adelaide, Adelaide, Australia. 2. School of Health and Related Research, The University of Sheffield, Sheffield, UK. 3. Department of Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon. 4. Non-Communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa.
Abstract
OBJECTIVE: To summarize data on the rates and predictors of left atrial thrombus/left atrial appendage thrombus (LAT/LAAT) detection by transoesophageal echocardiography (TEE) before electrical cardioversion (ECV) or catheter ablation (CA) for atrial fibrillation (AF). METHODS: EMBASE, MEDLINE, and Web of Science Core Collection were searched to identify all studies providing relevant data and published by October 7, 2020. A random-effects meta-analysis method was used to pool effect size estimates. RESULTS: A total of 85 studies were included, reporting data from 56 660 patients with AF. In patients undergoing CA and ECV, the pooled prevalence of LAT/LAAT was 1.8% and 7.5% in those not on oral anticoagulation (OAC), 1.8% and 5.5% in those taking OAC, and 1.3% and 4.9% in case of adequate OAC, respectively. According to the type of OAC, the prevalence was 2.0% and 7.6% for vitamin K antagonist, 1.3% and 3.5% for direct oral anticoagulant. Predictors of LAT/LAAT detection were nonparoxysmal AF (odds ratio [OR]: 3.6, 95% confidence interval: 2.4-5.2), hypertension (OR: 2.9, 1.2-7.0), previous stroke (OR: 3.0, 1.6-5.63), heart failure (OR: 4.3, 2.7-6.8), and CHADS2 score ≥2 (OR: 3.3, 1.9-5.8) for patients undergoing CA; and heart failure (OR: 2.8, 1.3-6.2) and the CHA2 DS2 -VASc score (OR: 2.55, 1.5-4.5) for those undergoing ECV. CONCLUSION: The prevalence of LAT/LAAT in AF patients undergoing ECV or CA varies widely, mainly due to differences in patient risk profiles and OAC types. Further research should determine whether the predictors of LAT/LAAT detection identified by this study could be used to select patients who require preprocedural TEE.
OBJECTIVE: To summarize data on the rates and predictors of left atrial thrombus/left atrial appendage thrombus (LAT/LAAT) detection by transoesophageal echocardiography (TEE) before electrical cardioversion (ECV) or catheter ablation (CA) for atrial fibrillation (AF). METHODS: EMBASE, MEDLINE, and Web of Science Core Collection were searched to identify all studies providing relevant data and published by October 7, 2020. A random-effects meta-analysis method was used to pool effect size estimates. RESULTS: A total of 85 studies were included, reporting data from 56 660 patients with AF. In patients undergoing CA and ECV, the pooled prevalence of LAT/LAAT was 1.8% and 7.5% in those not on oral anticoagulation (OAC), 1.8% and 5.5% in those taking OAC, and 1.3% and 4.9% in case of adequate OAC, respectively. According to the type of OAC, the prevalence was 2.0% and 7.6% for vitamin K antagonist, 1.3% and 3.5% for direct oral anticoagulant. Predictors of LAT/LAAT detection were nonparoxysmal AF (odds ratio [OR]: 3.6, 95% confidence interval: 2.4-5.2), hypertension (OR: 2.9, 1.2-7.0), previous stroke (OR: 3.0, 1.6-5.63), heart failure (OR: 4.3, 2.7-6.8), and CHADS2 score ≥2 (OR: 3.3, 1.9-5.8) for patients undergoing CA; and heart failure (OR: 2.8, 1.3-6.2) and the CHA2 DS2 -VASc score (OR: 2.55, 1.5-4.5) for those undergoing ECV. CONCLUSION: The prevalence of LAT/LAAT in AFpatients undergoing ECV or CA varies widely, mainly due to differences in patient risk profiles and OAC types. Further research should determine whether the predictors of LAT/LAAT detection identified by this study could be used to select patients who require preprocedural TEE.
Authors: Agnieszka Kapłon-Cieślicka; Monika Gawałko; Monika Budnik; Beata Uziębło-Życzkowska; Paweł Krzesiński; Katarzyna Starzyk; Iwona Gorczyca-Głowacka; Ludmiła Daniłowicz-Szymanowicz; Damian Kaufmann; Maciej Wójcik; Robert Błaszczyk; Jarosław Hiczkiewicz; Katarzyna Łojewska; Katarzyna Mizia-Stec; Maciej T Wybraniec; Katarzyna Kosmalska; Marcin Fijałkowski; Anna Szymańska; Mirosław Dłużniewski; Maciej Haberka; Michał Kucio; Błażej Michalski; Karolina Kupczyńska; Anna Tomaszuk-Kazberuk; Katarzyna Wilk-Śledziewska; Renata Wachnicka-Truty; Marek Koziński; Paweł Burchardt; Piotr Scisło; Radosław Piątkowski; Janusz Kochanowski; Grzegorz Opolski; Marcin Grabowski Journal: J Clin Med Date: 2022-05-11 Impact factor: 4.964
Authors: Beata Uziębło-Życzkowska; Agnieszka Kapłon-Cieślicka; Marek Kiliszek; Monika Gawałko; Monika Budnik; Katarzyna Starzyk; Beata Wożakowska-Kapłon; Ludmiła Daniłowicz-Szymanowicz; Damian Kaufmann; Maciej Wójcik; Robert Błaszczyk; Jarosław Hiczkiewicz; Katarzyna Łojewska; Katarzyna Mizia-Stec; Maciej T Wybraniec; Katarzyna Kosmalska; Marcin Fijałkowski; Anna Szymańska; Aleksandra Gos; Maciej Haberka; Michał Kucio; Błażej Michalski; Karolina Kupczyńska; Anna Tomaszuk-Kazberuk; Katarzyna Wilk-Śledziewska; Renata Wachnicka-Truty; Marek Koziński; Paweł Burchardt; Paweł Krzesiński Journal: Nutrients Date: 2022-09-04 Impact factor: 6.706